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Abstract
Background: Activation of glial cells, including astrocytes and microglia, has been implicated in the inflammatory
responses underlying brain injury and neurodegenerative diseases including Alzheimer’s and Parkinson’s diseases.
Although cultured astrocytes and microglia are capable of responding to pro-inflammatory cytokines and
lipopolysaccharide (LPS) in the induction and release of inflammatory factors, no detailed analysis has been carried
out to compare the induction of iNOS and sPLA2-IIA. In this study, we investigated the effects of cytokines (TNF-
alpha, IL-1beta, and IFN-gamma) and LPS + IFN-gamma to induce temporal changes in cell morphology and
induction of p-ERK1/2, iNOS and sPLA2-IIA expression in immortalized rat (HAPI) and mouse (BV-2) microglial cells,
immortalized rat astrocytes (DITNC), and primary microglia and astrocytes.
Methods/Results: Cytokines (TNF-alpha, IL-1beta, and IFN-gamma) and LPS + IFN-gamma induced a time-
dependent increase in fine processes (filopodia) in microglial cells but not in astrocytes. Filopodia production was
attributed to IFN-gamma and was dependent on ERK1/2 activation. Cytokines induced an early (15 min) and a
delayed phase (1 ~ 4 h) increase in p-ERK1/2 expression in microglial cells, and the delayed phase increase
corresponded to the increase in filopodia production. In general, microglial cells are more active in responding to
cytokines and LPS than astrocytes in the induction of NO. Although IFN-gamma and LPS could individually induce
NO, additive production was observed when IFN-gamma was added together with LPS. On the other hand, while
TNF-alpha, IL-1beta, and LPS could individually induce sPLA2-IIA mRNA and protein expression, this induction
process does not require IFN-gamma. Interestingly, neither rat immortalized nor primary microglial cells were
capable of responding to cytokines and LPS in the induction of sPLA2-IIA expression.
Conclusion: These results demonstrated the utility of BV-2 and HAPI cells as models for investigation on cytokine
and LPS induction of iNOS, and DITNC astrocytes for induction of sPLA2-IIA. In addition, results further
demonstrated that cytokine-induced sPLA2-IIA is attributed mainly to astrocytes and not microglial cells.
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Activation of glial cells, including astrocytes and micro-
glial cells, has been implicated in the inflammatory
responses in brain injury and in neurological diseases
such as Alzheimer’sd i s e a s e ,P a r k i n s o n ’sd i s e a s ea n d
stroke [1-5]. Astrocytes and microglia are two distinct
types of glial cells in the central nervous system. Despite
obvious differences in morphology and functional prop-
erties, they are regarded as immune active cells and in
some instances, they share common innate immune
responses. For example, both astrocytes and microglial
cells have been shown to respond to pro-inflammatory
cytokines and lipopolysaccharide (LPS) in the induction
of iNOS as well as other inflammatory factors [6-11].
However, difficulties in obtaining pure and large quanti-
ties of astrocytes and microglial cells in primary cultures
have led to studies using immortalized cells. In recent
years, immortalized microglial cells, such as the murine
derived BV-2 cells, have been extensively used as cell
models to elucidate signaling pathways and responses to
pro-inflammatory cytokines and LPS [9,12].
The secretory phospholipase A2 (sPLA2) family is
comprised of a group of low molecular mass enzymes
[13], and sPLA2-IIA has long been regarded as an
inflammatory protein associated with infection and car-
diovascular diseases [14,15]. In the central nervous sys-
tem, upregulation of sPLA2-IIA has been shown in rat
brain in response to focal cerebral ischemic injury
[16,17], as well as in the human Alzheimer brain as
compared with age-matched controls [18]. Upregulation
of sPLA2-IIA expression is also found in the rat model
for spinal cord injury [19,20]. Studies with cultured cells
have shown the ability for astrocytes to induce sPLA2-
IIA in response to pro-inflammatory cytokines [21-23].
However, whether cytokines and LPS can induce
sPLA2-IIA expression in activated microglial cells has
not been investigated in detail. Due to a point-shift
mutation in many murine species [24], studies to inves-
tigate sPLA2-IIA expression have been limited to astro-
cytes and microglial cells derived from rat brains. The
rat-derived Highly Aggressive Proliferating Immortalized
microglial cells (HAPI) were derived from mixed glial
cultures in rat brains [25]. While the HAPI cells show
many similarities to BV-2 cells, there are obvious differ-
ences in inflammatory responses comparing HAPI, BV-
2, and primary microglial cells [26]. In this study, the
murine BV-2 cells, rat HAPI microglial cells, and the
middle T-antigen derived immortalized astrocytes (type
II) from rat diencephalon (DITNC) together with pri-
mary astrocytes and microglial cells were used to exam-
ine induction of iNOS and sPLA2-IIA expression by
pro-inflammatory cytokines (TNFa,I L - 1 b,a n dI F N g)
and by LPS+IFNg.
Methods
Materials
Dulbecco’s modified Eagle’s medium (DMEM), penicil-
lin, streptomycin, 0.05% (w/v) trypsin/EDTA, and phos-
phate-buffered saline (PBS) were obtained from GIBCO-
BRL (Gaithersburg, MD, USA). Cytokines (TNFa, IL-1b,
and IFNg) were purchased from R & D Systems (Min-
neapolis, MN, USA). Lipopolysaccharide (LPS) (rough
strains) from Escherichia coli F583 (Rd mutant) were
purchased from Sigma-Aldrich (St. Louis, MO, USA).
Fetal bovine serum was from Atlanta Biologicals (Law-
renceville, GA, USA). Methylthiazolyldiphenyl-tetrazo-
lium bromide (MTT) was from Sigma-Aldrich (St.
Louis, MO, USA). Antibodies for Western blot are: (1)
sPLA2-IIA human, rabbit polyclonal antibody (BioVen-
dor, Candler, NC); (2) goat anti-rabbit IgG- horseradish
peroxidase (Santa Cruz Biotechnology, Santa Cruz, CA);
and (3) monoclonal anti-b-actin peroxidase (Sigma -
A l d r i c h ,S t .L o u i s ,M O ) .A n t i b o d i e sf o ri m m u n o h i s t o -
chemistry are: (1) anti-sPLA2-IIA polyclonal antiserum
(Cayman Chemical, Ann Arbor, MI); (2) anti-GFAP
monoclonal antibody for astrocytes (Millipore, Billerica,
MA); (3) CD11b antibody (Abcam Inc., cat # ab63317
Inc, Cambridge, MA); (4) fluorescein isothiocyanate
(FITC)-labeled goat anti-mouse and Texas red-labeled
goat anti-rabbit secondary antibody (Santa Cruz Bio-
technology, Santa Cruz, CA); and (5) Rhodamine-phal-
loidin (Molecular Probes, Eugene, OR) for F-actin.
Cell culture preparations and morphological examination
Preparations of primary astrocytes and microglial cells
involved pregnant Sprague-Dawley rats and C57BL/6
mice (Harlan, IN, USA) and 1-3 day-old pubs. All ani-
mal care and experimental protocol with post-natal
pups were carried out in accordance with NIH guide-
lines and with the University of Missouri Animal Care
and Use Committee (protocol #6728).
The immortalized mouse microglial cells (BV-2) were
originally obtained from Dr. R. Donato (University of
Perugia, Italy) and cultured as described previously [9].
Briefly, cells were cultured in 75 cm
2 flasks with DMEM
(high glucose) supplemented with 5% FBS containing
100 units/ml penicillin and 100 μg/ml streptomycin, and
maintained in 5% CO2 i n c u b a t o ra t3 7 ° C .F o rs u b c u l -
ture, cells were removed from the culture flask with a
scraper, re-suspended in the culture medium and sub-
cultured in 12-well (0.4 × 10
6) or 6-well (1.0 × 10
6)
plates for experiments. In some experiments, cells were
cultured in cover slips and used for immunostaining.
The immortalized rat microglial cell line HAPI was a
generous gift from Dr. J. Hong (Laboratory of Toxicol-
ogy and Pharmacology, National Institute of Environ-
mental Health Sciences, National Institute of Health,
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astrocytes, DITNC, were obtained from ATCC (Rock-
ville, MD, USA). Both HAPI and DITNC cells were cul-
tured in DMEM (high glucose), 10% FBS, 100 units/ml
penicillin, and 100 μg/ml streptomycin and maintained
in 5% CO2 at 37°C. To harvest HAPI microglia and
DITNC astrocytes, cells were treated with 0.05% tryp-
sin/EDTA for 2 minutes at 37°C, and centrifuged at 125
g for 10 min. The cell pellets were re-suspended in cul-
ture medium. Cell concentration was determined by
counting cells with a hemocytometer. Cells were subcul-
tured in 12-well (0.4 × 10
6) or 6-well (1.0 × 10
6)p l a t e s
for experiments.
Primary astrocytes were prepared from the cerebral
cortices of 1- 3 day-old Sprague-Dawley rats (Harlan,
IN, USA) as described by McCarthy and deVellis [27]
with slight modifications [28]. Briefly, cerebral cortices
were dissected and meninges removed. The tissues were
minced and suspended in 10 volumes 0.05% (w/v) tryp-
sin/EDTA and incubated for 10 min at 37°C. The cell
suspension was passed through a 14-gauge needle 5
times, and then filtered through 85 mm nylon mesh.
The filtrate was sedimented by centrifugation at 200 g
for 5 min and re-suspended in 10% FBS in DMEM con-
taining 100 units/ml penicillin and 100 μg/ml strepto-
mycin. Finally, cells were transferred to 75 cm
2 culture
flasks and fresh medium was changed the next day and
then every 2 days afterwards. When cells became con-
fluent, normally within 7-9 days, flasks were shaken at
200 rpm on an orbital shaker (Fisher Scientific, St.
Louis, MO) for 4 h at room temperature to remove
microglial cells. After shaking, cells were rinsed three
times with phosphate-buffered saline (PBS), suspended
in trypsin-containing solution as above, and subcultured
in 12-well plates for Griess reaction experiment and 6-
well plates for Western blot analysis. These cultures
contained over 95% astrocytes, as determined by immu-
nostaining for glial fibrillary acidic protein (GFAP). For
immunohistochemistry experiments, astrocytes were cul-
tured on Poly-L-Lysine Coated Glass Coverslips (12 mm
Round No. 1 German Glass) (BD Biosciences, San Jose,
CA). Cells were starved for 4 h prior to experimentation
in serum free DMEM medium and followed by treat-
ments with different conditions as described.
For preparation of primary microglial cells, rat (Spra-
gue-Dawley) or mouse (C57BL/6) pups less than 4 days
of age were used. The protocol was similar to that used
for preparation of primary astrocytes. Briefly, after
removing the meninges, brain tissue was minced into
small pieces and trypsinized by incubating tissue at 37°C
for 20 min. Brain tissue was triturated with a pipet to
further dissociate clumps and filtered with a 70 μm cell
strainer. Cells were centrifuged at 1,200 rpm for 5 min
at 4°C, and pellet was suspended in 30 ml of complete
medium containing DMEM with high glucose, 10% FBS,
OPI (1 mM oxaloacetate, 0.45 mM pyruvate, and 0.2 U/
ml insulin), and GM-CSF (0.5 ng/ml) to enhance prolif-
eration of microglia. The cell suspension was added to
75 cm
2 flasks (about 6 brains per flask of 30 ml). Cells
were incubated in flasks until confluent for 7-10 days.
Microglial cells were separated from astrocytes and oli-
godendrocytes by shaking the flasks in a rotary platform
in a 37°C incubator at 200 rpm overnight. The superna-
tant, which was enriched with microglial cells, was then
removed and centrifuged at 1200 rpm for 45 min. The
microglia population was established by immunostaining
with CD11b antibody. Purity for these microglial cells
w a sd e t e r m i n e dt ob ea r o u n d9 5 %( d a t an o ts h o w n ) .
The cells were plated for experiments using complete
media without the GM-CSF.
In all experiments, cells were serum starved for 4 h
prior to adding cytokines and LPS. Cell morphology was
o b s e r v e db yu s i n gap h a s ec o n t r a s tN i k o nD I A P H O T
300 microscope attached with a CCD cool camera
linked to MagnaFire 2.1C software for image processing.
Representative bright field pictures were obtained using
a 20× objective lens.
Measurement of NO
Our previous studies demonstrated that NO production
in glial cells was mainly due to the induction of iNOS
[9]. Therefore, measurement of NO was used to repre-
sent the induction process. NO released from cells was
converted to nitrite in the culture medium, which was
determined using the Griess reagent. In this study, cells
were cultured in DMEM without phenol red. After
treating cells with cytokines and LPS, aliquots (200 μl)
of culture medium were transferred to test tubes and
incubated with 100 μl of the reagent A (1% (w/v) sulfa-
nilamide in 5% phosphoric acid, Sigma) for 10 minutes
at room temperature in the dark. This was followed by
incubation with 100 μl of reagent B (0.1%, w/v, N-1-
napthylethylenediamine dihydrochloride, Sigma) for 10
minutes at room temperature in the dark. After mixing,
100 μl of the purple/magenta solution was transferred
to a 96-well plate and the absorbance at 543 nm was
measured within 30 minutes in a plate reader. The dilu-
tion series of sodium nitrite (0-100 μM) was used to
generate the nitrite standard reference curve.
Western blot analysis
After treating cells with cytokines and LPS, cells were
washed twice with ice-cold phosphate-buffered saline
and harvested in lysis buffer containing 50 mM Tris-
HCl (pH 7.4), 1 mM EDTA, 100 mM NaCl, 0.1% SDS, 1
mM PMSF, 1 mM sodium orthovanadate, 1 μg/ml leu-
peptin, 1 μg/ml pepstatin, and 10 μg/ml aprotinin. The
extract was centrifuged at 10,000 × g for 15 minutes at
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tion was determined by using a BCA protein assay kit
(Pierce Biotechnology, Rockford, IL) according to the
manufacturer’s instructions. Equivalent amounts of pro-
tein (25 μg) for each sample were resolved in 12% Tri-
cine-SDS-PAGE at 120 V in duplicates. After
electrophoresis, proteins were transferred to 0.2 μm
PVDF membranes at 250 mA for 2 h. Membranes were
incubated in Tris-buffered saline, pH 7.4 (TBS) with
0.1% Tween 20 (TBS-T) containing 5% non-fat milk for
1 h at room temperature. The blots were then incubated
with sPLA2-IIA polyclonal antibody (1:2500; BioVendor,
Candler, NC) overnight at 4°C. After washing with TBS-
T, blots were incubated with goat anti-rabbit IgG-
horseradish peroxidase (1:5000; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) for 1 h at room temperature. The
blots were then washed three times with TBS-T. Immu-
nolabeling was detected by chemiluminescence (Super-
Signal West Pico, Pierce, Rockford, IL). For loading
control, the blots were reacted with monoclonal anti-b-
actin peroxidase (1:30,000, Sigma - Aldrich, St. Louis,
MO). For quantification, blots were scanned and the
intensity of protein bands was measured as optical den-
sity using the Quantity One program (BioRad, Hercules,
CA). sPLA2-IIA bands were detected at 15 kDa. Ratios
of sPLA2-IIA to b-actin were calculated for each
sample.
Immunohistochemistry
DITNC cells and primary astrocytes were plated onto
poly-L-lysine coated glass coverslips. After treatments,
cells were fixed in 4% paraformaldehyde in PBS (pH 7.4)
for 15 min at room temperature. After washing three
times with PBS, samples were incubated for 10 min with
PBS containing 0.5% Triton-X-100. Nonspecific binding
of antibodies was blocked by 5% normal goat serum
(NGS) for 1 h at room temperature. Cells were then
incubated overnight at 4°C in 0.5% NGS with anti-
sPLA2-IIA polyclonal antiserum (1:50, Cayman Chemi-
cal, Ann Arbor, MI), anti-GFAP monoclonal antibody
for astrocytes (1:50, Millipore, Billerica, MA), or anti-
CD11b antibody for microglial cells (1:100, Abcam Inc,
Cambridge, MA). The cells were washed with PBS and
incubated for 1 h at room temperature with fluorescein
isothiocyanate (FITC)-labeled goat anti-mouse and
Texas red-labeled goat anti-rabbit secondary antibody
(1:300, Santa Cruz Biotechnology, Santa Cruz, CA), and
finally washed again with PBS. Cells were incubated for
10 min with Hoechst 33342 (1: 1000, Invitrogen, Carls-
bad, CA) as a counter-stain for nuclei. Cover-slips were
then mounted onto microscope slides and fluorescent
intensity measurements were performed at room tem-
perature using the Olympus X-41 fluorescence micro-
scope and 40× objective lens.
For immunofluorescence staining of F-actin, BV-2 cells
in cover-slips were fixed with 4% paraformaldehyde for
20 min and permeabilized by 0.1% Triton X-100 in PBS
for 10 min. Non-specific binding was blocked with 5%
normal goat serum (NGS) in PBS at room temperature
for 30 min. Cells were then incubated in rhodamine-
phalloidin (Molecular Probes, Eugene, OR), diluted 1:100
in PBS for 30 min, and then mounted onto microscope
slides and examined using the Leica DMI4000 epifluores-
cence microscope with 40× objective lens.
RT-PCR
After treating cells with cytokines and LPS, total RNA
was isolated from cells using the TRIZOL reagent
(Sigma-Aldrich, MO, USA). The RNA quality and con-
centration was evaluated by Nanodrop ND-1000 spectro-
photometry (NanoDrop Technologies, Wilmington, DE).
OD260 was used for the concentration while OD260/
OD280 and OD260/OD230 were used to evaluate the qual-
ity, usually ~1.8-2.2. Total RNA (0.5 μg) was used for
reverse transcription to cDNA with oligo dT primers by
means of the Advantage RT-for-PCR Kit (Takara Bio,
Mountain View, CA) according to the manufacturer’s
instructions. The volume of cDNA used was 10 μl( f r o m
50 ng RNA). Amplification was carried out in an auto-
mated thermal cycler (Eppendorf, Hauppauge, NY) with
a 3-min denaturation step at 94°C, followed by 25 cycles
including 45 sec at 94°C, 30 sec at 59.5°C, and 30 sec at
72°C. All PCR amplifications were submitted to a final
10-min step at 72°C. Amplified samples were separated
on a 2% agarose gel containing ethidium bromide in TAE
buffer. After electrophoresis, the gel was viewed by the
Kodak electrophoresis documentation and analysis sys-
tem (Kodak, Rochester, NY). Primers for rat sPLA2IIA
are: sense 5’-CATGGCCTTTGGCTCAATTCAGGT-3’;
antisense 5’-ACAGTCATGAGTCACACAGCACCA-3’;
and rat G3PDH sense 5’-TGAAGGTCGGTGTCAACG-
GATTTGGC-3’;a n t i s e n s e5 ’-CATGTAGGCCAT-
GAGGTCCACCAC-3’ was used as a control.
Quantitation of filopodia
For study to quantitate filopodia in BV-2 microglia, cells
were cultured in 35 mm dish until 80% confluency.
Cells were serum starved for 4 h prior to treatment with
cytokines and LPS. Since thin processes (filopodia)
started to appear after cytokine treatment by 2 h, a 4 h
exposure time was used for quantitaion of filopodia. In
each treatment condition, cells were observed under the
phase contrast Nikon DIAPHOT 300 microscope and
three fields with comparable dell densities were chosen.
In each field, the total number of cells, as well as cells
containing filopodia (processes more than 2 mm), were
counted. Results are expressed as % of filopodia-contain-
ing cells against the total.
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Cell viability was determined using the MTT (3-(4, 5-
Dimethylthiazol-2-yl) -2, 5-diphenyltetrazolium bro-
mide) assay protocol. Briefly, cells cultured in 12-well
plates were treated with cytokines and LPS. After treat-
ment, the medium was removed and 1 ml of MTT
reagent (0.5 mg/ml) in serum free DMEM was added
into each well. Cells were incubated for 4 h at 37°C, and
after dissolving the formazan dye with DMSO, absorp-
tion was read at 540 nm.
Statistical analysis
Results are analyzed by one-way ANOVA followed by
Dunett’s multiple comparison tests, or two-way
ANOVA (V4.00; GraphPad Prism Software Inc., San
Diego, CA). Differences with p < 0.05 are considered
significant.
Results
Cytokines and LPS induce morphological changes in
microglial cells and astrocytes
Based on preliminary study and results in Table 1 treat-
ing BV-2 microglial cells with a mixture of three cyto-
kines (TNFa, IL-1b, and IFNg, at 10 ng/ml each) or LPS
(100 ng/ml) + IFNg (10 ng/ml) produce high levels of
NO. These conditions were used to examine cell mor-
phology and viability in different glial cell types. In this
study, cells were cultured to 90% confluency, and at 4 h
prior to treatment with cytokines and LPS, serum was
removed from the cultures and replaced with DMEM.
Bright field pictures depicting cell morphology with or
without cytokine and LPS treatments were obtained at
24 h using the inverted Nikon microscope. As shown in
Figure 1, control BV-2 and HAPI cells (incubated for 24
h under serum free condition) are mostly round with
bright refringency and small dark nuclei; whereas, cyto-
kine and LPS treatments for 24 h caused cells to
become ramified and some are star shaped with short
thick processes. Removal of serum retarded cell growth
but did not cause morphological changes (data not
shown). Control and treated primary mouse and rat
microglial cells (derived from primary astrocytes) show
similar morphology and responses as compared to
immortalized microglial cells (Figure 1).
DITNC astrocytes are triangular shape with spindle-
like features, and after treatment with the three cytokine
mixture, they became dark with a bright refringency,
but did not show obvious morphological changes as
compared with microglial cells (Figure 1). Primary rat
astrocytes are larger flat cells with irregular shape, and
they do not show obvious morphological changes after
exposure to cytokines and LPS (Figure 1).
We determined cell viability at 24 h after treating BV-
2, HAPI, and DITNC astrocytes with cytokines and LPS
+I N F g using the MTT assay protocol. In BV-2 cells, no
change in MTT values was observed after exposure with
the three cytokine mixture or LPS + INFg for 12 h (Fig-
ure 2A). However, there are obvious decreases in MTT
values in BV-2, HAPI, and DITNC cells at 24 h after
exposure to cytokine and LPS + INFg (Figures 2B-2D).
Cytokines and LPS elicit different temporal profile for p-
ERK1/2 between BV-2 microglia and DITNC astrocytes
Although earlier studies had demonstrated involvement
of the MEK1/2-ERK1/2 pathway in cytokine-induced
sPLA2 in DITNC astrocytes [21] and iNOS in BV-2
cells [9], a time course study to compare p-ERK1/2 acti-
vation in these two cell types was not carried out. As
shown in Figure 3A, exposure of BV-2 cells to the three
cytokine mixture showed a biphasic increase in p-ERK1/
2; first a transient earlier phase peaking at 15 min, and
then a second phase increase from 1 to 4 h. Exposure of
BV-2 cells to LPS + IFNg did not show the early phase
increase, but a similar second phase of increase from 1
to 4 h (Figure 3B). Exposure of DITNC astrocytes to the
three cytokine mixture indicated an early phase increase
at 15 min and a second increase at 1 h (Figure 3C).
Exposure of DITNC astrocytes to LPS + IFNg also
showed an early phase increase in pERK1/2 at 5 min
and a subsequent phase at 2 h (Figure 3D). Unlike the
BV-2 cells, DITNC astrocytes did not show a dramatic
increase in p-ERK1/2 between 1 to 4 h.
Cytokines induce time-dependent cytoskeletal changes
and increase in filopodia in microglial cells
We further examined the time course for morphological
changes after exposing BV-2 cells to the three cytokine
mixture. As shown in Figure 4A, exposure of cytokines
Table 1 NO production by cytokines and LPS in different glial cell types
Cell types (number) Con TNFa+IL1b IFNg TNFa+IL1b+ IFNg LPS LPS+IFNg
BV-2 (1 × 10
5) - - 31.0 ± 0.5 69.5 ± 2.1 12.3 ± 2.4 79.1 ± 2.5
HAPI (1 × 10
5) - - 17.2 ± 0.5 22.4 ± 0.5 12.9 ± 0.9 39.9 ± 0.7
DITNC (1 × 10
5) - - - 9.0 ± 0.2 - -
RPA (3 × 10
5) - - - 4.6 ± 1.2 - -
Results are expressed as NO in μM and are means ± SD from three experiments.
RPA, rat primary astrocytes
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HAPI
Control TNFD + IL-1E + IFNJ LPS + IFNJ
BV-2
HAPI
Control TNFD + IL-1E + IFNJ LPS + IFNJ
Mouse 
primary
microglia
Rat
Primary
microglia
Mouse 
primary
microglia
Rat
Primary
microglia
DITNC
Rat primary
astrocytes
DITNC
Rat primary
astrocytes
Figure 1 Cytokines (mixture of TNFa, IL-1b, IFNg) or LPS + IFNg alter morphology of microglial cells and astrocytes. Cells were cultured
in 12-well plates and serum starved for 4 h before treatment with the three cytokine mixture (3 cyt) containing TNFa, IL-1b, and IFNg at 10 ng/
ml each respectively, or LPS (100 ng/ml) + IFNg (10 ng/ml) for 24 h. Cell morphology was obtained by taking bright field pictures with an
inverted Nikon microscope (20×) at 24 h with and without (Control) treatment with cytokines and LPS. Photomicrographs are representative
pictures depicting BV-2 (murine) and HAPI (rat) microglial cells, mouse and rat primary microglial cells, and rat immortalized (DITNC) astrocytes
and rat primary astrocytes.
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Page 6 of 15to BV-2 cells caused the cells to become elongated with
protrusion of short fine processes (filopodia) as early as
1 h. The filopodia continued to become elongated with
time and by 8 h, nearly all cells showed filopodia and
some have flat pancake-like structures with ruffled edges
at the end (red arrows). With increasing time, filopodia
started to disappear between 12 to 16 h leaving cells
with stout processes as shown in Figure 1. HAPI cells
show a similar time-dependent increase in filopodia as
in BV-2 cells (data not shown).
S i n c ef i l o p o d i aw e r ep r o d u c e da f t e re x p o s i n gB V - 2
cells to the three cytokine mixture (TNFa,I L - 1 b,a n d
IFNg)a n dL P S+I F N g, we further examined filopodia
formation by treating cells with individual cytokines and
LPS. As shown in Figure 4B, among the three cytokines
tested, filopodia were only induced by IFNg. Although
LPS alone could also induce filopodia formation, the
addition of IFNg further enhanced formation of these
processes (Figure 4B).
Since ERK activation has been shown to participate in
IFNg-mediated signaling pathways and cell migration
[29,30], we tested whetherp - E R K 1 / 2p l a y sar o l ei n
IFNg-induced filopodia formation. In this experiment,
BV-2 cells were cultured in cover slips and serum
starved for 4 h. After preincubated for 30 min with
U0126 (10 μM), a specific inhibitor for MEK/ERK, they
were exposure to IFNg for 4 h. After the 4 h treatment,
cells were subsequently stained for F-actin with rhoda-
mine-phalloidin, a high-affinity F-actin probe. As shown
in Figure 4C and 4D, exposing cells to IFNg for 4 h
resulted in formation of filopodia (white arrows). Treat-
ment of cells with 10 μM of U0126 caused the cells to
become round, and pretreatment of U0126 prior to
exposure to IFNg completely abrogated the formation of
filopodia induced by IFNg.
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Figure 2 Assay for cell viability after treating microglial cells and astrocytes with cytokine mixture or LPS + IFNg.B V - 2a n dH A P I
microglial cells and DITNC astrocytes cultured in 12-well plate were serum starved for 4 h followed by exposure to the three cytokine mixture (3
cyt) or LPS + IFNg for the respective time indicated. Cell lysates were obtained for MTT assay. Results are mean ± SD from n = 3. **p < 0.01 vs.
control (Con).
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Page 7 of 15Cytokines and LPS induce NO production in different glial
cell types
Our earlier studies demonstrated that NO production
upon exposure of BV-2 cells to IFNg and LPS is due
mainly to induction of iNOS expression [9]. In this
s t u d y ,at i m ec o u r s ee x p e r i m e n tt oc o m p a r eN Op r o -
duction due to the three cytokine mixture and LPS +
IFNg indicated a detectable increase from 12 h to 24 h
(Figure 5A and 5B). A similar time course for NO pro-
duction was observed with the HAPI cells. In a subse-
quent experiment, induction of NO by individual
cytokines and LPS was examined in BV-2, HAPI,
DITNC and primary rat astrocytes after 24 h exposure.
Similar to studies observed with BV-2 cells [9], TNFa +
IL-1b could not induce NO in any of the cell types
tested (Table 1). However, IFNg alone can induce NO in
both BV-2 and HAPI microglial cells and IFNg
enhanced NO production induced by LPS (Table 1).
Under similar conditions, DITNC and primary rat astro-
cytes did not respond to IFNg, but low levels of NO can
be observed after exposure to the three cytokine mixture
(Table 1).
We further tested whether rat primary microglial cells
(RPM) are capable of responding to cytokines and LPS.
Due to difficulty in controlling cell numbers in the RPM
preparations, data are based on the amount of proteins
in the culture dish. As shown in Figure 5C, stimulation
of RPM by cytokines and LPS produced similar levels of
NO as compared to that in BV-2 cells.
Induction of sPLA2-IIA mRNA and protein expression by
cytokines and LPS in different glial cell types
In our previous studies, induction of sPLA2-IIA expres-
sion by cytokines had been mainly limited to assay of
mRNA expression because of lacking suitable antibodies
for protein detection [21,22,28]. Furthermore, informa-
tion about induction of this inflammatory enzyme by
microglial cells had also been lacking. In this study, we
established a similar pattern for individual cytokines and
LPS to induce sPLA2-IIA mRNA and protein expression
in DITNC astrocytes. These results clearly indicated the
capability for TNFa,I L - 1 b and LPS, but not IFNg,t o
induce sPLA2-IIA mRNA expression (Figures 6A and
6B) and protein expression (Figures 6C and 6D) in
DITNC cells. The highest level of expression was
observed after treating cells with the three cytokine mix-
ture. However, when primary astrocytes were treated
with cytokines and LPS under similar conditions as for
DITNC astrocytes, sPLA2-IIA protein expression was
observed only after treatment with the three cytokine
mixture (Figure 6E).
We further examined the ability for BV-2 and HAPI
cells, as well as primary rat microglial cells, to respond
to cytokines and LPS in the induction of sPLA2-IIA
mRNA and protein expression. In this study, samples
from DITNC astrocytes were used as a positive control.
The lack of response in BV-2 cells is expected because
these cells are of murine origin. However, it is surprising
that cytokines and LPS could not induce sPLA2-IIA
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Figure 3 Time course for p-ERK1/2 and total ERK1/2 expression after treating BV-2 and DITNC cells to the three cytokine mixture or
LPS + IFNg. BV-2 and DITNC cells were serum starved for 4 h and exposed to 3 cyt or LPS + IFNg. Cells lysates were obtained at
indicated times and subjected to Western blot. Results are representative blots from three independent experiments.
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Page 9 of 15mRNA, and protein expression in HAPI cells that are of
rat origin (Figure 7A and 7B). In order to further con-
firm that the lack of response is not due to the immor-
talization procedure, we tested primary mouse and rat
microglial cells and showed that neither cell type could
respond to cytokines and LPS to produce sPLA2-IIA
(Figure 7C). These results demonstrate that despite the
active response to cytokines and LPS in induction of
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Figure 5 Cytokines or LPS + IFNg induce NO production in
different glial cell types. (A and B) BV-2 cells were serum starved
in phenol red free DMEM for 4 h prior to treatment with the three-
cytokine mixture (A) or LPS + IFNg(B). At the respective time points,
culture media were collected for determination of NO using the
Greiss reaction protocol as described in the text. Data are mean ±
SD from three independent experiments. **p < 0.01 vs. values at 12
h. One-way ANOVA, Dunnett’s multiple comparison tests. (C)
Comparing NO production between BV-2 microglial cells and rat
primary microglial cells (RPM) based on protein in the dish. Results
on RPM preparation have been repeated.
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Figure 6 Cytokines induce sPLA2-IIA mRNA and protein
expression in DITNC, and primary astrocytes. After exposing
DITNC astrocytes to TNFa, IL-1b, IFNg, and LPS for 24 h, sPLA2-IIA
mRNA expression was determined by RT-PCR (A), and protein
expression was determined by Western blot (C). Quantitative data
are expressed as relative density to G3PDH (sPLA2-IIA vs. G3PDH) (B)
or to b-actin (sPLA2-IIA vs. b-actin) (D). Results are mean ± SD from
three independent experiments (*p < 0.05, **p < 0.01 vs. control,
One-way ANOVA, Dunnett’s multiple comparison test). (E) Only the
three cytokines mixture could cause induction of sPLA2-IIA in
primary astrocytes.
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Page 10 of 15iNOS, microglial cells lack the ability to cause induction
of sPLA2-IIA mRNA and protein under cell culture
conditions.
Cytokines and LPS increase sPLA2-IIA immunoreactivity in
DITNC and primary astrocytes
In this study, we have successfully used rabbit polyclonal
antibodies against human sPLA2-IIA from BioVendor
(Candler, NC) for Western blots, but these antibodies
were not suitable for immunocytochemical study.
Instead, testing with anti-sPLA2-IIA polyclonal anti-
serum from Cayman Chemical (Ann Arbor, MI)
appeared to give positive immunostaining of sPLA2-IIA
in DITNC cells and primary rat astrocytes. As shown in
Figure 8A, DITNC cells are positive for GFAP, and an
increase in sPLA2-IIA immunoreactivity can be shown
upon exposing cells to the three cytokine mixture and
LPS + IFNg for 24 h (Figure 8A). Treatment with pri-
mary astrocytes with the three cytokine mixture for 48
h also showed an increase in sPLA2-IIA immunoreactiv-
ity (Figure 8B). However, double immunostaining of pri-
mary astrocytes with GFAP and sPLA2-IIA indicated
variances in GFAP and sPLA2-IIA immunoreactivity
after exposure to cytokines. In Figure 8B, we identified a
cell (pointed by the white arrow) showing little or none
immunoreactivity on GFAP, but substantial staining of
sPLA2-IIA. In addition, sPLA2-IIA immunoreactivity
appeared to be higher in differentiating cells containing
multiple nuclei.
Discussion
Using immortalized cell lines, we demonstrated substan-
tial differences between microglia (mouse BV-2 and rat
HAPI) and astroglia (DITNC) in their responses to pro-
inflammatory cytokines and endotoxins. Besides induc-
tion of iNOS and sPLA2-IIA, we also examined tem-
poral changes in cell morphology, e.g., formation of
filopodia in microglial cells, and upregulation of p-
ERK1/2. Thus, information provided by this study is
important for selection of cell types as models for test-
ing anti-inflammatory and anti-oxidative compounds on
inflammatory responses.
A time course study ranging from 5 min to 4 h indicated
that the three cytokines or LPS + IFNg could induce tran-
sient early and late phase increases in p-ERK1/2 expres-
sion in BV-2 microglial cells and DITNC astrocytes
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Figure 7 Cytokines or LPS + IFNg did not induce sPLA2-IIA in microglial cells. sPLA2-IIA mRNA (A) and protein (B) were determined by RT-
PCR and Western blot in BV-2 and HAPI cells. In this experiment, sPLA2-IIA induced by DITNC astrocytes was used as positive control. (C) Rat
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one typical experiment which has been repeated.
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Page 11 of 15(Figure 3). The dramatic increase in p-ERK1/2 during 1 to
4 h in BV-2 cells is of particular interest because this
increase appears to correlate well with the time for filopo-
dia production (Figure 4A). In agreement with the lack of
filopodia production in DITNC astrocytes, these cells did
not show a precipitous increase in p-ERK1/2 expression
during 1 to 4 h. Studies to further test the induction of
filopodia in BV-2 cells by individual cytokines revealed the
role of IFNg and its downstream pathway leading to acti-
vation of ERK1/2 (Figure 4D). A study by Nakamura et al.
also observed morphological changes in microglial cells
upon exposure to LPS [31]. However, our results here pro-
vide further evidence of a link between IFNg and ERK1/2
for induction of filopodia.
IFNg is known to cause activation of the JAK/STAT
pathway, and similar to earlier studies [9], results here
A
B
Figure 8 sPLA2-IIA immunoreactivity in DITNC and primary astrocytes. (A) DITNC cells were cultured on coverslips and stimulated with
cytokines or LPS + IFNg for 24 h. (B) primary astrocytes were treated with cytokines or LPS + IFNg for 48 h. After exposure to cytokines and LPS,
cells were permeabilized and double-immunostained with GFAP (left, green) and sPLA2-IIA (middle, red) with merged images (right). Scale bar
represents 20 μm.
Sheng et al. Journal of Neuroinflammation 2011, 8:121
http://www.jneuroinflammation.com/content/8/1/121
Page 12 of 15demonstrated that IFNg alone could induce NO produc-
tion in BV-2 and HAPI cells as well as rat primary
microglial cells (data not shown). Besides the interferon
regulating factor (IRF-1) and STAT1, transcription fac-
tors such as NF-B are present in the promoter of the
iNOS gene [32]. In human macrophages, ERK1/2 activa-
tion is critical for phosphorylation of STAT1 induced by
IFNg [29]. The ability for IFNg alone to induce iNOS in
microglial cells is an indication that IFNg receptor can
activate signaling molecules and downstream pathways
leading to activation of NF-B .O u re a r l i e rs t u d yi n d i -
cated differences in ERK1/2 activation and temporal
changes in PKCδ in the induction of iNOS by IFNg and
LPS [9]. More recently, a study by Jung et al. also indi-
cated IFNg-induced JAK/STAT and ERK1/2 signaling
pathways for expression of iNOS [33].
Data in Table 1 show that under similar treatment
conditions with a comparable number of cells plated to
the well, BV-2 cells are generally more responsive to
cytokines and LPS in the induction of NO as compared
to HAPI cells. Based on results in Figure 5C, BV-2 cells
are comparable to rat primary microglia in production
of NO. Study by Horvath et al. [26] showed low NO
production in LPS-stimulated BV-2 cells as compared to
primary microglia and HAPI cells. One possible differ-
ence is the absence of IFNg in the study by Horvath et
al. [26]. In our study, DITNC and primary rat astrocytes
showed considerably lower NO as compared to micro-
glial cells. It is recognized that inflammatory responses
in cultured cells can be modified by a number of factors,
including the animal source of the cells, culture condi-
tions, seeding density, levels of cytokines and LPS, and
time for removal of serum [34]. For example, decreasing
serum in culture media could cause morphological
changes in HAPI cells [25]. In addition, studies using
primary astrocytes need to be particularly cautious
about the presence of microglial cells, which may rapidly
proliferate upon exposure to cytokines and LPS. In fact,
an immunostaining study with primary astroglia/micro-
glia preparations indicated that cytokine-induced iNOS
is mainly attributed to microglia and not astrocytes [35].
Our results here showed low but detectable levels of
NO upon exposing immortalized (DITNC) and primary
astrocytes (after removing microglial cells) to cytokines.
In primary and immortalized astrocytes of rat origin,
induction of sPLA2-IIA can be mediated independently
by TNFa and IL-1b, without the involvement of IFNg
[21,22,28,36]. Since BV-2 cells are of murine origin, it is
not surprising that these cells lack the ability to induce
sPLA2-IIA upon exposure to cytokines. However, we
were surprised to find that the immortalized HAPI cells,
which are of rat origin, also lacked the ability to respond
to cytokines and LPS in the induction of sPLA2-IIA
(Figure 7A and 7B). Testing with rat primary microglial
cells isolated from primary astrocytes further provided
data confirming the lack of ability for microglial cells to
induce sPLA2-IIA in response to cytokines and LPS
(Figure 7C).
In this study, we observed upregulation of sPLA2-IIA
immunoreactivity in DITNC astrocytes and in primary
astrocytes upon exposure to cytokines and LPS + IFNg
(Figure 8A and 8B). These results are in agreement with
observation of sPLA2-IIA in astrocytes in rat brain after
focal cerebral ischemic insult [16] and in the Alzheimer
brain as compared to age-matched controls [18]. How-
ever, double staining with sPLA2-IIA and GFAP in pri-
mary astrocytes after exposure to cytokines indicated
variances in GFAP and sPLA2-IIA immunoreactivity
(Figure 8B). The one cell showing low GFAP but high
sPLA2-IIA immunoreactivity suggests that cells other
than astrocytes may be present in the primary culture,
and that primary astrocytes may undergo different
stages of differentiation after exposure to cytokines.
Study by Titsworth et al. observed upreguation of
sPLA2-IIA in oligodendroglial cells in response to spinal
cord injury [20]. Obviously, further studies are needed
to investigate mechanism for upregulation of sPLA2-IIA
in different glial cell types under in vivo and in vitro
conditions.
Conclusions
This study attempts to lay the ground work for using
immortalized glial cells for neuroinflammatory
responses, induction of NO and sPLA2-IIA. Our results
demonstrated a time-dependent increase in filopodia
production upon exposure of microglial cells to IFNg,
and the dependence of ERK1/2 activation for this pro-
cess. Our results further showed the ability for immorta-
lized microglial cells (BV-2 and HAPI) to produce high
levels of NO in response to pro-inflammatory cytokines
or LPS while they lack the ability to induce sPLA2-IIA.
On the other hand, the immortalized astrocytes
( D I T N C )p r o v e dt ob eas u i t a b l ec e l ll i n ef o rs t u d i e st o
elucidate signaling pathways for cytokines to induce
sPLA2-IIA expression.
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